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Abstract 26 
Presenilin-1 (PS1) is the catalytic component of the γ-secretase complex. In this study, 27 
we explore if PS1 participates in the processing of the cholinergic acetylcholinesterase 28 
(AChE). The major AChE variant expressed in the brain is a tetramer (G4) bound to a 29 
proline-rich membrane anchor (PRiMA). Over-expression of the transmembrane 30 
PRiMA protein in CHO cells expressing AChE and treated with the γ-secretase inhibitor 31 
N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT) have 32 
enabled us to study whether, through its γ-secretase activity, PS1 participates in the 33 
processing of PRiMA-linked AChE. γ-Secretase inhibition led to a notable increase in 34 
the level of PRiMA-linked AChE, suggesting that γ-secretase is involved  in the 35 
cleavage of PRiMA. We demonstrate that cleavage of PRiMA by γ-secretase results in a 36 
C-terminal PRiMA fragment. Immunofluorescence labelling allowed us to identify this 37 
PRiMA fragment in the nucleus. Moreover, we have determined changes in the 38 
proportion of the raft-residing AChE-PRiMA in a PS1conditional knockout mouse. Our 39 
results are of interest as both enzymes have therapeutic relevance for Alzheimer’s 40 
disease. 41 
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1. Introduction  42 
The accumulation of the β-amyloid peptide (Aβ) in the brain, together with the 43 
abnormal phosphorylation of the tau protein, are significant features for Alzheimer’s 44 
disease (AD) pathogenesis (Blennow et al., 2006). The Aβ polypeptide arises from the 45 
proteolytic processing of a larger transmembrane protein, the amyloid precursor protein 46 
(APP), through the successive cleavage by enzymes called secretases. Sequential 47 
cleavage by β-secretase cleaving enzyme (BACE) and γ-secretase produces the Aβ 48 
peptide fragment. Alternative processing occurs if APP is first processed by a 49 
metalloproteinase, α-secretase, instead of BACE, resulting in a membrane-bound C-50 
terminal fragment which is also a γ-secretase substrate, but generating non-51 
amyloidogenic products (for a review see Thinakaran and Koo, 2008). γ-Secretase is a 52 
protein complex consisting of presenilin, nicastrin, APH-1 (anterior pharynx-defective 53 
1), and PEN-2 (presenilin enhancer 2) (Kaether et al., 2006). Presenilin-1 (PS1), an 54 
aspartyl protease that cleaves substrates within the cell membrane, is the catalytic 55 
subunit of the γ-secretase complex. 56 
Many other type-I integral membrane proteins are also known to be cleaved by 57 
γ-secretase, after a prior shedding by α-secretase or β-secretase (for a review see Lleó 58 
and Saura, 2011). We have recently demonstrated an interaction between the 59 
acetylcholine-hydrolyzing enzyme, acetylcholinesterase (AChE), and the catalytic γ-60 
secretase component PS1 (Silveyra et al., 2008; 2012). The brain cholinergic variant of 61 
AChE (a tetramer of active subunits) is anchored to the plasma membrane through a 62 
non-catalytic subunit, a type 1 transmembrane protein called PRiMA (proline-rich 63 
membrane anchor) (Perrier et al., 2002; Chen et al., 2011). Thus, the PRiMA subunit is 64 
an accessory partner for the cellular disposition of AChE (Dobbertin et al., 1999), and 65 
represents a limiting factor for production of the tetrameric AChE (G4)-PRiMA 66 
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complex (Perrier et al., 2003). PRiMA expression is predominantly associated to the 67 
cholinergic system and strongly co-localizes with AChE within the neurons and 68 
particularly at the plasma membrane (Henderson et al., 2010). PRiMA consists of a 69 
signal peptide, an extracellular domain that contains a proline-rich motif, a 70 
transmembrane domain, and a cytoplasmic domain (Noureddine et al., 2007). Indeed, 71 
during the progression of AD, AChE activity decreases in the cerebral cortex and other 72 
affected areas, and a major tetrameric form containing the PRiMA subunit is markedly 73 
altered, while monomeric forms of AChE are relatively preserved  (Atack et al., 1983; 74 
Fishman et al., 1986; Sáez-Valero et al., 1999). 75 
The possibility of spontaneous and evoked release of a soluble form of AChE 76 
within different brain areas has been demonstrated in vivo in several rodent species 77 
(Greenfield and Shaw, 1982; Appleyard and Smith, 1987; Appleyard et al., 1989), a 78 
process that is likely mediated by secretion (Anglade et al., 1999). Moreover, recently 79 
the participation of a metalloproteinase activity, likely α-secretase, has been proposed in 80 
the shedding process of plasma membrane-anchored AChE (Hicks et al., 2011; 2013). 81 
Subsequent processing of the membrane anchor subunit PRiMA, and the potential 82 
physiological consequences have been not investigated to date. 83 
In this study we investigate whether PS1 participates in the processing of the 84 
cholinergic AChE form via cleavage of the PRiMA subunit, and whether PRiMA 85 
fragments could translocate to the nucleus. Using PS1 conditional knockout mice (PS1 86 
cKO; Yu et al., 2001), we have also examined whether PS1 influences the localization 87 
of PRiMA-linked G4 AChE in brain lipid rafts in vivo. 88 
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2. Material and methods  89 
2.1. Cell culture and treatments 90 
Chinese hamster ovary (CHO) cells stably over-expressing the human AChE-T variant 91 
(a generous gift from H. Soreq, The Institute of Life Sciences, The Hebrew University 92 
of Jerusalem) were cultured in DMEM+GlutaMAX™-I (Dulbecco’s Modified Eagle 93 
medium; GIBCO Invitrogen Corporation) supplemented with 10% foetal bovine serum 94 
(FBS), penicillin (100 U/mL), streptomycin (100 µg/mL) and G-410 (200 µg/mL), and 95 
maintained at 37ºC in saturated humidity containing 95% air and 5% CO2. Complete 96 
depletion of AChE from FBS was achieved by passing the seum through edrophonium-97 
Sepharose (Flores-Flores et al., 1996). Cells were seeded at a density of 8×105 cells on 98 
35 mm tissue culture dishes. CHO cells were transfected with 4 μg of PRiMA plasmid 99 
cDNA using Lipofectamine™ 2000 (Invitrogen) according to the manufacturer's 100 
instructions. The cDNA encoding the full length mouse PRiMA isoform I was tagged 101 
with an HA epitope (YPYDVP DYA) inserted before the stop codon at the C-terminus. 102 
A pCI “empty” vector (Promega, Madison, WI, USA) served as negative control. After 103 
48 hours of the transfection, the cells were washed two times with phosphate-saline 104 
buffer (PBS) and resuspended in 120 µL ice-cold extraction buffer: 50 mM Tris-HCl, 105 
pH 7.4 / 150 mM NaCl / 5 mM EDTA / 1% (w/v) Nonidet P-40 / 0.5% (w/v) Triton X-106 
100 supplemented with a cocktail of protease inhibitors. The cell lysates were sonicated 107 
and centrifuged at 70,000×g at 4 ºC for 1 hour, and the supernatants were collected and 108 
frozen at -80ºC prior to assaying for AChE and PRiMA. 109 
CHO cells stably overexpressing wild-type human PS1 and wild-type APP 110 
(PS70, a generous gift from Dr. Selkoe; see Xia et al., 1997), were cultured in 111 
OPTIMEM supplemented with 10% FBS, and G-418 (200 µg/mL), and puromicin (2.5 112 
µg/mL). These cells were transfected with 2 μg of PRiMA DNA and 2 μg of plasmid 113 
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DNA encoding the human AChE-T under the cytomegalovirus (CMV) promoter-114 
enhancer (Soreq and Seidman, 2001). Cells were collected for analysis 48 hours after 115 
the transfection.  116 
Transfected cells were treated with 0.1, 0.5, 1, 5 or 10 µM of the γ-secretase 117 
inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT; 118 
Calbiochem), or vehicle (DMSO, Sigma-Aldrich Co). Alternatively, the α-secretase 119 
inhibitor Batimastat (25 µM) or the BACE inhibitor 2-β-Secretase Inhibitor III, GL189 120 
(H-EVNstatineVAEF-NH2; 5 µM), both from Calbiochem, Merck Chemicals, were 121 
used. Following 24 hours of treatment, cells were collected for analysis. 122 
For some experiment, cells over-expressing AChE and PRiMA were treated for 123 
24 hour with the neurotoxin from snake venom fasciculin-2 (Fas2; 2 nM; Abcam), 124 
which binds AChE with high affinity (Bourne et al., 2003), or with the monoclonal anti-125 
AChE antibody HR2 (dilution 1:1000; ABR-Affinity BioReagents). 126 
Cell viability following each treatment (as previously described) was tested in 127 
cells cultured in 96-well plates using the tetrazolium assay (MTS; CellTiter 96® 128 
AQueous Assay, Promega), according to the manufacturer’s instructions. 129 
 130 
2.2. PS1 conditional knockout mice and tissue preparation 131 
All animal procedures were approved by the Universidad Miguel Hernandez’s Animal 132 
Care and Use Committee. Brain samples were collected from ten 2.5 to 3.5 month-old 133 
PS1conditional knockout mice (PS1 cKO; see Yu et al., 2001) and 10 age-matched 134 
littermates in a C57BL6/129 hybrid background (all generously provided by C.A. Saura, 135 
Institut de Neurociències, Universitat Autònoma de Barcelona, Spain). PS1 expression 136 
has been selectively eliminated in the postnatal forebrain of these cKO mice beginning 137 
at P18.  No PS1 immunoreactivity is detected in the brains of these mice at 2–3 months 138 
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of age.  In addition, no significant alterations in normal brain cytoarchitecture, neuronal 139 
number or morphology, general behaviour, motor coordination, or exploratory anxiety 140 
was observed in these mice (Yu et al., 2001; Saura et al., 2004). 141 
Brain cortices were homogenized (10% w/v) in extraction buffer: 50 mM Tris-142 
HCl, pH 7.4 / 500 mM NaCl / 5 mM EDTA / 1% (w/v) Nonidet P-40 / 0.5% (w/v) 143 
Triton X-100 supplemented with a cocktail of protease inhibitors (Sáez-Valero et al., 144 
1993). The homogenates were sonicated and centrifuged as described above and the 145 
supernatants were collected and frozen at -80ºC until assay.  146 
Raft membrane subdomains were isolated at 4ºC, as described previously but 147 
with minor modifications (Xie et al., 2010a). Briefly, brain cortices (1g/10 ml) were 148 
homogenized at 9,500 rpm (IKA, Staufen, Germany), six times (10 sec each time) in 149 
buffer A (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM benzamidine HCl, 10µg/ml 150 
aprotinin, 10µg/ml leupeptin. Homogenized tissues were then sonicated three times at 151 
low intensity (0.5 sec periods, with 30 sec intervals to avoid overheating). The sonicated 152 
preparation was centrifuged at 500 g for 5 min to remove cell debris and nuclei, and the 153 
post-nuclear fraction was centrifuged at 35,000 rpm for 30 min in a Sorvall TST 60.4 154 
rotor. The resulting pellet was washed and re-suspended by sonication in 600 µl of 155 
buffer A containing 5% glycerol. This pellet was used as the total membrane fraction. 156 
For analysis of membrane rafts, a 500 µl sample of the total membrane fraction was 157 
incubated with 0.1% Triton X-100 on ice for 1 h and applied to a discontinuous flotation 158 
gradient.  This fraction was then mixed with an equal volume of 80% sucrose in buffer 159 
A, placed at the bottom of a 4 mL ultracentrifugation tube, and overlaid with 2.4 mL of 160 
buffer A containing 30% sucrose followed by 0.6 ml of buffer A containing 5% sucrose. 161 
The resulting discontinuous gradient was spun at 50,000 rpm in a Sorvall TST 60.4 162 
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rotor for 18 h at 4 °C. Fourteen fractions of ~250 µl were collected from the top of the 163 
tube and used for various assays. 164 
 165 
2.3. Nuclear protein fractionation 166 
CHO PS70 cells were cultured in T25 flasks (8×105 cells/ plate). Two days after 167 
transfection with PRiMA and AChE-T, cells were washed twice with cold PBS, and 168 
gently scraped off the plates with 10 mL of cold PBS. Cell debris was discarded by 169 
centrifugation for 5 min at 500×g, 4ºC. Cell lysis and isolation of cellular nuclei were 170 
performed using the QProteome Nuclear Protein kit (Qiagen), according to the 171 
manufacturer's instructions. Cytosolic and nuclear protein fractions were assayed by 172 
Western Blotting using α-tubulin and acetylated histone H2B as internal markers. 173 
 174 
2.4. Immunoprecipitation of PRiMA-HA 175 
Immunoprecipitations were carried out at 4º C by incubating samples overnight with the 176 
antibodies coupled to protein A-sepharose using dimethyl pimelimidate dihydrochloride 177 
(Sigma-Aldrich Co). Immune complexes were eluted with glycine. For PS1 178 
immunoprecipitation, extracts from CHO-AChE cells transfected with PRiMA were 179 
incubated with the 98/1 anti-PS1 antibody (Evin et al., 2001) and analysed by Western 180 
blotting using an anti-HA antibody. For PRiMA-HA immunoprecipitations extracts 181 
from CHO-PS1 cells transfected with PRiMA and AChE-T were incubated with the 182 
anti-HA antibody (Sigma-Aldrich Co) and analysed by Western blotting using an anti-183 
PRiMA antibody. Extracts incubated with protein A-sepharose coupled to a non-specific 184 
rabbit IgG (Vector), were analyzed as negative controls. 185 
 186 
2.5. AChE enzymatic assay and protein determination 187 
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A modified microassay version of the colorimetric Ellman’s method was used to 188 
measure AChE (Sáez-Valero et al., 1993), using 50 μM tetraisopropyl 189 
pyrophosphoramide (iso-OMPA) as a specific inhibitor for the structurally related 190 
butyrylcholinesterase, an enzyme that coexists with AChE. Total protein concentrations 191 
were determined using the bicinchoninic acid method (Pierce).  192 
 193 
2.6. Sedimentation analysis 194 
Molecular forms of AChE were separated according to their sedimentation coefficients 195 
by centrifugation on 5-20% (w/v) sucrose gradients containing 0.5% (w/v) Triton X-196 
100. Ultracentifugation was performed at 150,000×g in a SW 41Ti Beckman rotor for 197 
18 hr, at 4ºC. Approximately 40 fractions were collected from the bottom of each tube 198 
and assayed for AChE activity to identify individual AChE forms (G4 = tetramers; G1 = 199 
monomers) by comparison with the position of molecular weight markers, catalase 200 
(11.4S) and alkaline phosphatase (6.1S). We defined the ratio of AChE forms G4/G1 as 201 
the proportion of G4 molecules versus the light form, G1.  202 
 203 
2.7. Western blotting, measurement of PRiMA by ELISA and Phosphatase 204 
alkaline assays  205 
Twenty to fifty micrograms of protein from cell lysates (equal amount of protein in each 206 
lane) or 40 µL of each lipid raft fraction were separated by SDS-PAGE electrophoresis. 207 
Samples were denatured at 50ºC for 15 min (PS1) or 98ºC for 7 min (all other proteins). 208 
The separated proteins were transferred to nitrocellulose membranes (Schleicher & 209 
Schuell Bioscience GmbH) and probed with the following primary antibodies: anti-210 
AChE antibody E-19 (Santa Cruz Biotech); anti-N-terminal PS1 (Calbiochem); anti HA 211 
(Sigma-Aldrich); anti-C-terminal PRiMA (Leung et al., 1999). An anti-GAPDH 212 
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antibody (Abcam) was used as a loading control. Antibodies against flotilin 2 (BD 213 
Biosciences) was used as a lipid raft marker, whilst antibodies against calnexin (Sigma-214 
Aldrich Co) and anti-β-cop (Thermo Scientific Pierce) were used as non-raft markers.  215 
An antibody against acetylated histone H2B (AcH2B) (generous gift of Dr. A. Barco) 216 
was used to distinguish the nuclear fraction, and an α-tubulin (Sigma-Aldrich Co) 217 
antibody was used to distinguish the cytosolic fraction. Western blots for different 218 
antibodies were performed separately to avoid re-probing of blots. The blots were 219 
incubated with the corresponding secondary antibody conjugated to horseradish 220 
peroxidase and the signal was detected using the ECL Plus detection reagent according 221 
to the manufacturer’s instructions (GE Healthcare) in a Luminescent Image Analyzer 222 
LAS-1000 Plus (FUJIFILM). For semi-quantitative analysis, protein levels were 223 
normalized to GADPH and the intensity of bands was measured by densitometry with 224 
the Science Lab Image Gauge v4.0 software provided by FUJIFILM. 225 
PRiMA levels in cortical extracts from PS1 cKO mice were determined using 226 
specific enzyme-linked immunosorbent assays (ELISA) (Cusabio Biotech Co, Hubei, 227 
China) according to the manufacturer's instructions. 228 
Alkaline phosphatase (AP) was measured using 0.75 mM p-229 
nitrophenylphosphate in 0.1 mM diethanolamine buffer, pH 9.8. One unit (U) of AP 230 
activity is equal to one nmol of p-nitrophenol formed per min. 231 
 232 
2.8. Confocal microscopy  233 
CHO-PS1 cells were transfected with human PRiMA tagged to HA using Lipofectamine 234 
2000 (Invitrogen) according to the manufacturer’s instructions. After 4 hours, the 235 
medium was replaced with fresh medium containing 5 μM DAPT, or the equivalent 236 
volume of DMSO as vehicle control. After 24 hours, cells were washed with cold 237 
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Hank´s buffered salt solution and fixed with methanol for 10 min at -20ºC. Non-specific 238 
sites were blocked with 2% (w/v) BSA and 40 µg/mL digitonin in PBS for 30 min.  239 
Cells were then incubated with anti-HA antibody (rabbit, Sigma-Aldrich) for 1 hour 240 
followed by the secondary antibody (Cy5 anti-rabbit, GE-Healthcare) for 1 hour. After 241 
two washes with cold HBSS, cells were incubated briefly with Hoechst 33258 dye to 242 
label nuclei (Invitrogen). Pictures were acquired in a Leica upright TCL-SL confocal 243 
microscope using an HCX Plan Apochromat 63×/1.32-0.6 NA oil objective. To measure 244 
the intensity of PRiMA-HA fluorescence in the nucleus, a circle was hand drawn over 245 
the blue fluorescence of the Hoechst dye in the merge channel, and the red fluorescence 246 
from PRiMA-HA that overlapped this fluorescence was quantified. Analysis was 247 
performed with LAS AF Lite software. Non-transfected cells were used as controls, and 248 
non-specific fluorescence was not detected. 249 
Human H4 neuroglioma cells were seeded on glass coverslips and transiently co-250 
transfected with 300 ng of each of the AChE-T, PRiMA and PS1-GFP constructs in 251 
serum-free media using the XtremeGene9 DNA transfection reagent (Roche Diagnostics 252 
GmbH) according to the manufacturer’s instructions. FBS (10%) was added to the 253 
media 4 hours after transfection. After 24 hours, the lipid rafts were labeled as described 254 
previously (Guardia-Laguarta et al., 2009). Briefly, cells on the glass coverslips were 255 
incubated with Cholera Toxin Subunit B (CT-B) tagged with an Alexa-694 fluorophore 256 
(Molecular Probes, Inc) followed by an anti-CT-B antibody (Molecular Probes, Inc) to 257 
crosslink lipid rafts into distinct patches on the plasma membrane. Cells were washed 258 
twice with PBS, fixed with 4% paraformaldehyde and then  immunostained for AChE 259 
with the anti-AChE N19 antibody (Santa Cruz Biotetechnology) followed by an 260 
Alexa647-tagged secondary antibody (Molecular Probes, Inc). Confocal images were 261 
taken with a SP5 confocal microscope (Leica Microsystems GmbH, Wetzlar, Germany) 262 
García-Ayllón et al. 12 
using a 63× objective (4× zoom) in three channels; 488nm (PS1-GFP), 561nm (lipid 263 
rafts) and 647nm (AChE-T). Laser power was kept at a low gain to avoid crossover 264 
between the three channels and to avoid pixel saturation. Confocal images were taken in 265 
multiple z planes (1micron apart) in order to capture the entire cell. All z planes were 266 
used for quantification of co-localization. Only the z plane at the midpoint of the cell 267 
was used for the confocal images presented here.  Co-localization analysis was 268 
performed using ImageJ software (v1.46g) (Schneider et al., 2012). The three confocal 269 
channels (AChE, PS1 and lipid rafts) containing multiple z stacks across the cell were 270 
individually thresholded using the Otsu method implemented in ImageJ in order to 271 
create a binary image. Manders’ coefficients (Manders, 1993) for pair-wise co-272 
localization of either AChE-T and lipid rafts, AChE-T and PS1, or PS1 and lipid rafts 273 
were calculated for the binary threshold images using the JACoP ImageJ plug-in (Bolte 274 
and Cordelieres, 2006). The Manders’ coefficients correspond to the fraction of pixels 275 
that are positive for the first protein that are also positive for the second, with a value of 276 
1 representing 100% co-localization and 0 being 0% co-localization. Images showing 277 
the pixels where the two channels co-localize were generated for the binary threshold 278 
images using the co-localization highlighter ImageJ plug-in. 279 
 280 
2.9. Statistical analysis 281 
All data were analysed using SigmaStat (Version 2.0; SPSS Inc.) by Student’s t-test 282 
(two tailed). Results are presented as means ± SEM. p values < 0.05 were considered 283 
significant.284 
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3. Results 285 
3.1. PRiMA interacts with PS1 and undergoes proteolytic processing 286 
We previously demonstrated an interaction between PS1 and AChE, and the co-287 
immunoprecipitation of G4 AChE with PS1 antibodies (Silveyra et al., 2008). To 288 
confirm that this interaction occurs in AChE forms containing the PRiMA subunit, we 289 
used an anti-PS1 antibody to co-immunoprecipitate PRiMA in CHO cells stably over-290 
expressing the AChE-T variant (CHO-AChE) and co-transfected with a C-terminal HA 291 
tagged PRiMA subunit. Sedimentation analysis by sucrose density gradients was used to 292 
characterize AChE molecular forms, and to confirm the expression of PRiMA-linked 293 
G4 AChE in transfected CHO cells (Fig. 1A). Two PRiMA bands of ~22 and ~20 kDa 294 
were observed in all cellular extracts by western blot analysis with an anti-HA antibody 295 
(Fig. 1B). These two bands likely correspond to mature (fully glycosylated) and 296 
immature PRiMA (Chan et al., 2012). The specificity of the signal was confirmed in 297 
PS1 immunoprecipitates using an anti-PRiMA antibody (Fig. 1B). The PriMA signal 298 
was not detected in the negative immunoprecipitation controls, using a non-specific 299 
rabbit IgG antibody (Fig. 1C). 300 
We next examined if γ-secretase was able to mediate PRiMA processing. CHO-301 
AChE cells, co-transfected with PRiMA were treated with a well-known γ-secretase 302 
inhibitor DAPT, which has been demonstrated to reduce levels of Aβ in cell culture and 303 
in vivo (Lanz et al., 2003). The efficiency of DAPT to inhibit γ-secretase activity was 304 
monitored by measuring the accumulation of the APP C-terminal fragment (APP-CTF) 305 
in cells treated for 24 hours with 5 μM of DAPT (Fig. 2A). In cells treated with DAPT, 306 
a trend towards a decrease in soluble (secreted) AChE activity was observed, albeit that 307 
this was not statistically significant when compared to controls (12± 5%; p= 0.1). 308 
Conversely, a small but statistically significant increase (16± 6%; p= 0.03) in the 309 
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cellular AChE activity was observed compared to untreated cells (Fig. 2B). Specifically, 310 
the levels of PRiMA-linked G4 AChE were increased in DAPT-treated cells, with 311 
minimal change in monomeric G1 (the species devoid of PRiMA subunit), leading to a 312 
significant increase in G4/G1 ratio (Fig. 2C). The concomitant increase in PRiMA 313 
content (180± 40%; p< 0.001; Fig. 2D) in DAPT-treated cells, compared to untreated 314 
controls, suggests that PS1 can cleave PRiMA at the membrane spanning domain by 315 
preventing γ-secretase processing. A dose-dependent effect of DAPT treatment on 316 
PRiMA accumulation is observed (Supporting material, Fig. S1). No significant change 317 
in cell viability was observed following 24 hours of treatment with any of the secretase 318 
inhibitors, as assessed by the MTS method. 319 
These results suggest that PRiMA-linked G4 AChE is a new target of γ-320 
secretase. However, since C-terminal fragments of PRiMA (PRiMA-CTF) were not 321 
detected in this cell line, it is possible that they were present at sub-detectable levels and 322 
is indicative of the inherent instability of these fragments. To investigate this further, 323 
CHO cell line stably transfected with PS1 (CHO PS70 cells, hereafter referred to as 324 
CHO-PS1), which exhibit elevated γ-secretase activity (Xia et al., 1997), were 325 
transfected with AChE-T and PRiMA tagged to HA at the C-terminus in an attempt to 326 
identify the PRiMA-CTF. A ~14 kDa band was detected by the anti-HA antibody 327 
corresponding to the expected size of PRiMA-CTF (Fig. 3A). The specificity of the 328 
band was confirmed by immunoprecipitation with an anti-HA antibody and Western 329 
blotting using anti-PRiMA antibody (an antibody raised to the C-terminus of PRiMA; 330 
Fig. 3B).  331 
Moreover, accordingly with the expected sequential actions of secretases, a first 332 
one, α- or β-secretase, is expected to cleave PRiMA-linked AChE before shedding of 333 
PRiMA anchor by γ-secretase. Thus, we also monitored, under the same conditions used 334 
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for DAPT treatment, the efficiency of α- and β-secretase specific inhibitors to target 335 
PRiMA-linked AChE by determining changes in AChE release and in the cellular levels 336 
of PRiMA.  Treatment of the cells with batimastat, a matrix metalloproteinase inhibitor 337 
which has previously been shown to influence AChE release (Hicks et al., 2013), 338 
prevented AChE release and increased PRiMA levels (Fig. 4). Interestingly, treatment 339 
with GL189, a specific inhibitor commonly used to block the BACE proteolytic activity 340 
of solubilized membrane fractions (Capell et al., 2002), also led to increased levels of 341 
PRiMA but the it failed to alter the levels of secreted AChE activity (Fig. 4). 342 
We next determined whether the addition of an AChE inhibitor or an AChE 343 
antibody to the cell system, and hence associated conformational changes in the 344 
complex, would affect the processing of PRiMA. Fas2 is a strong AChE inhibitor that 345 
binds to the PAS (peripheral anionic site) rather than the active site of AChE; while 346 
HR2 is an antibody raised against human cerebellar AChE. Neither of the assayed 347 
compounds were able to induce changes in PRiMA levels (Supporting material Fig. S2), 348 
revealing that epitopes involved in these interaction are unrelated with secretase 349 
processing. 350 
 351 
3.2. Localization of PRiMA immunoreactivity in the cell nucleus 352 
Several transmembrane proteins have been demonstrated to undergo γ-secretase 353 
cleavage, releasing soluble intracellular fragments which translocate to the nucleus and 354 
act as transcriptional regulators (Rochette and Murphy, 2002). In contrast, other 355 
transmembrane proteins, processed by γ-secretase, are only cleaved for degradation (for 356 
a review see Lleó and Saura, 2011). Immunofluorescence labeling of nuclear DNA by 357 
DAPI allowed us to examine the presence of PRiMA-HA in the nucleus of CHO-PS1 358 
cells transfected with PRiMA. Localization of PRiMA-HA immunoreactivity confirmed 359 
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that PRiMA-CTF enters the nucleus. The level of the nuclear PRiMA-HA signal was 360 
decreased in transfected cells treated with DAPT compared to controls (45 ±3% 361 
decrease, p= 0.002; Fig. 5A). Western blotting of HA immunoprecipitates from nuclear 362 
extracts corroborated the presence of a PRiMA-CTF in the nuclear fraction (Fig. 5B). 363 
 364 
3.3. Co-localization of PS1 and AChE in membrane rafts 365 
Since PS1 has been described as a lipid raft resident protein (Parkin et al., 1999; Wada 366 
2003; Vetrivel 2004), and PRiMA can target G4 AChE to membrane rafts (Xie et al., 367 
2010a), we investigated whether both PS1 and PRiMA-AChE co-localize to lipid rafts. 368 
The distribution of PS1 and AChE was compared by immunocytochemistry in H4 cells 369 
(a cell line widely used for lipid raft studies; Hinz et al., 2004; Asai et al., 2007; 370 
Guardia-Laguarta et al., 2009) over-expressing both AChE-T and PRiMA subunits (Fig. 371 
6). Confocal microscopy analysis demonstrated that ~42% of total AChE and ~10% of 372 
total PS1 co-localized with lipid rafts in H4 cells. Within the lipid rafts, ~23% of AChE 373 
co-localized with PS1 and conversely ~26% of PS1 co-localized with AChE. 374 
 375 
3.4. The PRiMA-linked G4 AChE form is increased in lipid rafts of the PS1 cKO 376 
mouse brain 377 
To assess whether γ-secretase is involved in the control of PRiMA-linked G4 AChE 378 
levels in vivo, total AChE activity, AChE isoforms and PRiMA levels were measured in 379 
brain homogenates from 3-month-old PS1 cKO mice (Yu et al., 2001) and littermate 380 
controls. No significant differences were detected in total AChE activity, PRiMA levels 381 
or in the contribution of each AChE molecular form in PS1 cKO mice compared with 382 
littermate controls (Supporting material Fig. S3). Analyses of membrane raft 383 
preparations were then conducted in the PS1 cKO mice to examine if PS1 influences the 384 
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localization (and/or processing) of AChE into brain lipid rafts in vivo. To prepare raft-385 
enriched fractions, membrane pellets from brain cortices were treated with 0.1% Triton 386 
X-100 at 4°C and extracts subjected to flotation in discontinuous sucrose gradients. 387 
Raft-associated proteins, flotillin-2 (Volonte et al., 1999) and alkaline phosphatase 388 
(Parkin et al., 1997); and non-raft proteins, calnexin and β-cop (García-Marcos et al., 389 
2006), were used to characterize raft enriched fractions (Fig. 7A). In the membrane 390 
preparations obtained from cortices of wild-type mice, the majority of the PS1 391 
immunoreactivity was associated with raft membranes, whereas AChE was identified in 392 
both raft and non-raft fractions (Fig. 7B). The proportion of raft-localized AChE was 393 
higher in samples from PS1 cKO mice than wild type mice, resulting in increased values 394 
for a quotient between raft-associated AChE and non-raft AChE, enabling the 395 
distinction between PS1 cKO mice and littermate controls (Fig. 7C).  Sedimentation 396 
analysis confirmed that the PRiMA-linked G4 form is the major, if not the only, AChE 397 
form associated with rafts in both groups of mice (Fig. 7D). 398 
399 
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4. Discussion 400 
The loss of cholinergic neurons in the forebrain and the associated decline of cholinergic 401 
neurotransmission are features of AD (Davies and Maloney, 1976; Perry et al., 1977). 402 
The AChE enzyme, as part of the cholinergic system, is decreased in the brain of AD 403 
subjects, where the cholinergic PRiMA-linked G4 form is particularly affected (Atack et 404 
al., 1983; Fishman et al., 1986). Other molecular forms and variants of AChE are 405 
present in lower quantities within the brain. These include soluble G4 isoforms and light 406 
forms, mainly monomers, of the T ('tailed') variant (Sáez-Valero et al., 1993; 1999); and 407 
also monomers of the minor R ('readthrough') variant (Berson et al., 2003). The 3’ 408 
alternative splicing of ACHE also generates additional N-terminally extended AChE 409 
variants (Meshorer et al., 2004). All molecular forms and variants of AChE display 410 
similar catalytic activity, however, the structural polymorphism of AChE differs within 411 
cellular compartments and between different cell types (for a review see Massoulié, 412 
2002). It has been proposed that different molecular forms of AChE may have different 413 
physiological functions, other than its classical cholinergic role (Small et al., 1996; 414 
Grisaru et al., 1999). These polymorphisms enable the localization of AChE into 415 
particular cellular compartments. Individual components can be sorted separately by this 416 
fine regulation of AChE function (either the classical cholinergic activity or other 417 
activities), either by the protein itself or in combination with other protein partners. 418 
Recent studies have demonstrated that a significant portion of the membrane-bound G4 419 
AChE is localized in membrane rafts within the brain and that PRiMA directs this 420 
restricted localization (Xie et al., 2010a, 2010b). This suggests that the targeting of 421 
PRiMA-linked AChE to rafts in the brain may account for its synaptic localization and 422 
function. It is thus important to elucidate which particular AChE molecular forms are 423 
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affected in the AD brain, and within which particular cell compartment they reside, in 424 
order to optimize therapies. 425 
In this study, we show that PS1, the catalytic component of the γ-secretase 426 
complex, can interact with the PRiMA subunit. Our data demonstrate that secretases can 427 
participate in the processing of PRiMA-linked AChE, and that PS1/γ-secretase cleaves 428 
PRiMA in a cellular model. We were also able to characterize a single 14-kDa PRiMA 429 
C-terminal fragment, and localize PRiMA immunoreactivity in the nucleus. 430 
Furthermore, the silencing of PS1 in the PS1 cKO mouse model led to changes in the 431 
distribution of PRiMA-linked G4 AChE forms in raft and non-raft membranes.  432 
We have previously demonstrated that expression of the PS1-A246E pathogenic 433 
mutation in transgenic mice leads to decreased brain AChE activity (Silveyra et al., 434 
2008). Reciprocally, AChE influences PS1 levels as AChE over-expression increases 435 
PS1 levels, while AChE knock-down with siRNA leads to decreased PS1 in transfected 436 
cells (Silveyra et al., 2011). An inter-relationship between signaling and amyloid 437 
processing has been reported for neuroligin-1, a postsynaptic adhesion molecule whose 438 
extracellular domain is homologous to AChE, and which is sequentially cleaved by α-439 
secretase/ADAM10 and PS1/γ-secretase (Suzuki et al., 2012). This proteolytic 440 
processing of neuroligin-1 is regulated by synaptic NMDA receptor activation or 441 
interaction with soluble neurexin ligands (Suzuki et al., 2012). Whether neuronal 442 
activity regulates PS1-mediated AChE processing, and under what biological 443 
conditions, remain to be determined. It has been previously suggested that AChE 444 
shedding is related with activation of the α7 nicotinic acetylcholine receptor, and also 445 
with metabolism of APP, associated with the location of AChE into lipid raft domains 446 
(Hicks et al., 2011; 2013). 447 
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APP, one of the most investigated  γ-secretase substrates, is alternatively 448 
processed through the successive actions of β-secretase and γ-secretase (amyloidogenic 449 
pathway), or by α-secretase and γ-secretase (non-amyloidogenic pathway). More than 90 450 
type-I integral membrane proteins are known to be cleaved by γ-secretase; most of them 451 
are previously processed uniquely by α-secretase or by β-secretase, and some, similarly 452 
to APP, can be processed by both secretases (see Lleó and Saura, 2011). It is therefore 453 
important to identify the protease that cleaves PRiMA-linked G4 prior to γ -secretase 454 
processing. Identification of these proteases will enable the design of strategies to 455 
interfere with its processing. We found that treatments with inhibitors of both, α-456 
secretase or β-secretase, resulted in accumulation of PRiMA. Cellular treatment with 457 
batimastat, a matrix metalloproteinase inhibitor with effects in several enzymes 458 
possessing α-secretase activity, led to a significant reduction in AChE activity in the 459 
conditioned media, while, interestingly, no effect of the β-secretase inhibitor GL189 was 460 
observed. The mechanism by which AChE is released is still unclear. Our data 461 
corroborate the possibility that a metallosecretase was involved in AChE secretion 462 
(Hicks et al., 2013), while processing of PRiMA-linked AChE by β-secretase and γ-463 
secretase may result in the degradation of the active AChE subunits. More research is 464 
needed in order to characterize difference between both pathways. 465 
Also in this regard, it has been suggested that AChE may be targeted for 466 
endocytosis (Hu et al., 2009). Despite a large proportion of PS1 localized within the 467 
endoplasmic reticulum and early Golgi, it is assumed that APP cleavage occurs on the 468 
cell surface and in endosomes/lysosomes, where proteolytically active PS1/γ-secretase is 469 
principally localized (for a review see Haass et al., 2012). A putative domain related 470 
with endocytosis has been identified in the cytoplasmic tail of PRiMA (Hu et al., 2009). 471 
As regard with the pathological condition, this internalization pathway for AChE from 472 
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the cell surface to lysosomes appears to be influenced by extracellular Aβ (Hu et al., 473 
2009).  474 
The identification of PS1 (Vetrivel et al., 2004), and PRiMA-linked G4 isoforms 475 
(Xie et al., 2010a, 2010b) in lipid rats, and our results showing that PS1 and PRiMA-476 
AChE interact in vivo (Silveyra et al., 2008) suggest that the lipid rafts maybe the 477 
location of the PS1 and PRiMA-AChE interaction. Remarkably, and in accordance with 478 
the subcellular sites of PRiMA-linked AChE processing by γ-secretase, while β-479 
secretase activity is enriched within lipid rafts, alongside γ-secretase (Riddell et al., 480 
2001; Hatori et al., 2006), α-secretase is not localized to rafts (Harris et al., 2009). Our 481 
studies using H4 cells demonstrate that PS1 co-localizes in the same raft microdomain 482 
with AChE. This is further substantiated by the observation that localization of G4 483 
AChE into rafts is altered in PS1 cKO mice. The increased levels of raft-bound AChE in 484 
the PS1 cKO mice may arise from impaired proteolytic events resulting in decreased γ-485 
secretase activity, or from the influence of PS1 itself on the localization of AChE into 486 
rafts. PS1 co-precipitates both fully glycosylated (22-kDa band) and immature PRiMA 487 
(20-kDa band). PS1 has the capacity to alter both the lipid composition (Grimm et al., 488 
2006) and the lipid packing order of neuronal raft membranes (Eckert and Müller, 489 
2009). Increasing evidence points to the relevance of membrane composition of both 490 
raft and non-raft domains to AD progression in different AD models and in the human 491 
disease (Williamson and Sutherland, 2011). The possibility that perturbations in lipid 492 
rafts can influence not only APP metabolism, but also signaling events that may involve 493 
cholinergic neurotransmission has been suggested (Hicks et al., 2012). Our data 494 
corroborate this possibility. More interestingly, the inter-relationship between 495 
neurotransmission and amyloid processing is plausible. 496 
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For the known secretase substrates, γ-secretase is always the final enzyme that 497 
cleaves the membrane-spanning domain. In general, the requirements for being a γ-498 
secretase substrate are broad; a type I transmembrane helix with a small ectodomain 499 
(<300 amino acids), usually resulting from a prior shedding by a metalloprotease-like 500 
protease.  However the requirements for γ-secretase cleavage do not depend critically on 501 
a specific amino acid sequence or on endocytosis (Struhl and Adachi, 2000). Moreover, 502 
substrates such as Notch, CD44 or the β-C-terminal fragment (β-CTF) of APP are 503 
cleaved at multiple sites by γ -secretase, resulting in various cleavage products (Lleó and 504 
Saura, 2011). In spite of the lack for specific requirements to be a potential γ-secretase 505 
substrate, it is interesting to note that the expected membrane-bound C-terminal 506 
fragment of APP and PRiMA are similar in size (~40 to 47 amino acids for the APP 507 
intracellular domain and ~40 amino acids for PRiMA). It is also worth noting that 508 
several valine residues are present at the juxtamembrane domain of PRiMA, and it is 509 
known that γ-secretase cleaves close to valines (Maruyama et al., 1996). The 510 
identification of C-terminal fragments of PRiMA is consistent with the mechanism of 511 
action of γ-secretase.  512 
As γ-secretase cleavage of some substrates releases intracellular domains with 513 
critical signaling properties, further characterization of the generated intracellular 514 
fragment of PRiMA is required. While PRiMA intracellular fragments may be rapidly 515 
degraded, we have been able to monitor the production of a PRiMA C-terminal 516 
fragment and predict that it is translocated to the nucleus. In the absence from the 517 
PRiMA cytoplasmic tail of any of the nuclear localization signals (NLS) known to date, 518 
the possibility remains that the PRiMA fragment use an adaptor protein in its way to the 519 
nucleus. The identification of a PRiMA trans-acting cytoplasmic adaptor protein that 520 
participates and regulates the translocation will be valuable for understanding the role of 521 
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the PRiMA fragment in the cell nucleus. Although the occurrence of AChE in the 522 
nucleus has been described in the early stages of apoptosis (Yang et al., 2002; Huang et 523 
al., 2005), there is the possibility that the PRiMA segment participates in the regulation 524 
of gene transcription, a possibility that deserves thoroughly investigation.  525 
The physiological relevance of the proteolytic events described in this study is 526 
still not well understood. AChE inhibitors are currently at the forefront of AD therapy 527 
(Giacobini, 2003; Cummings, 2004; Lleó, 2007), and PS1 is a new emerging drug target 528 
(Wolfe, 2008; Wagner et al., 2012).  Understanding the relationship between PS1 and 529 
AChE may be useful not only for the physiopathology of the disease, but also to develop 530 
more effective Alzheimer therapies.531 
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7. Figure Legend 772 
 773 
Figure 1. PRiMA interacts with PS1. (A) Cellular extracts from CHO cells stably 774 
transfected with the AChE-T variant (CHO-AChE; open symbols) were co-transfected 775 
with the non-catalytic PRiMA subunit carrying a HA tag at its C-terminus (CHO-776 
AChE/PRiMA; closed symbols). The generation of the tetrameric G4 AChE form in 777 
CHO-AChE/PRiMA cells was assessed by ultracentrifugation in a continuous sucrose 778 
density gradient. (B) The over-expressed PRiMA subunit was identified by blotting with 779 
an anti-HA antibody or by an anti-C-terminal PRiMA antibody. Two PRiMA bands 780 
were identified at ~22 kDa (most likely the fully glycosylated mature protein; closed 781 
arrow-head) and ~20 kDa (immature protein; open arrow-head) in CHO-AChE/PRiMA 782 
cell extracts. (C) Cellular extracts from CHO-AChE/PRiMA cells were 783 
immunoprecipitated with an anti-N-terminal PS1 antibody. Precipitated proteins were 784 
immunoblotted with an anti-HA antibody. Two PRiMA bands at ~22 kDa and ~20 kDa 785 
were detected. Extracts incubated with protein A-Sepharose coupled with a non-specific 786 
rabbit IgG, were analyzed in parallel as negative controls. 787 
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 788 
Figure 2. Inhibition of γ-secretase increases levels of tetrameric AChE and of the 789 
linked PRiMA subunit. CHO cells stably transfected with the AChE-T variant and co-790 
transfected with PRiMA tagged to HA, were treated for 24 hours with 5 μM of DAPT or 791 
vehicle control (DMSO). (A) The presence of the C-terminal APP fragment indicates 792 
inhibition of γ-secretase activity by DAPT. (B) The relative percentage of soluble 793 
(secreted) and cellular AChE activity after the addition of DAPT or vehicle is shown. 794 
(C) Fractions from the sucrose density gradient were collected and assayed for AChE 795 
activity to identify individual AChE isoforms in extracts from cells treated with vehicle 796 
(DMSO; Control; closed symbols) or 5 µM DAPT (open symbols). The corresponding 797 
G4/G1 ratio was calculated in controls and in DAPT treated cells. (D) Immunoreactivity 798 
of PRiMA-HA from DAPT-treated cells. Each determination was made in duplicate. 799 
Data represent means ± SEM from at least 9 independent determinations from three 800 
independent experiments. *p < 0.05.   801 
 802 
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803 
Figure 3. Identification of a C-terminal fragment of PRiMA in CHO-PS1 cells. (A) 804 
CHO cells stably transfected with PS1 (CHO-PS1) were transfected with PRiMA tagged 805 
to HA at its C-terminus (CHO-PS1/PRiMA). The full-length PRiMA subunit and C-806 
terminal fragment were identified by blotting with an anti-HA antibody. (B) Cell 807 
extracts from CHO-PS1/PRiMA cells were immunoprecipitated with an anti-HA 808 
antibody and immunoprecipitated proteins (IP) were immunoblotted with an anti C-809 
terminal PRiMA antibody. The anti-HA antibody was able to immunoprecipitate both 810 
full length PRiMA (bands of ~22 kDa and ~20 kDa) and its CTF (~14 kDa). Negative 811 
controls were extracts incubated with protein A-sepharose coupled with rabbit IgG. 812 
 813 
 814 
 815 
 816 
 817 
 818 
 819 
 820 
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 821 
Figure 4. Inhibition of α-secretase and β-secretase increases levels of the PRiMA 822 
subunit. CHO cells overexpressing AChE-T and PRiMA (tagged to HA) were treated 823 
for 24 hours with 25 µM of the α-secretase inhibitor Batimastat, with 5 µM of the β-824 
secretase codenamed GL189, or with vehicle (control). (A) Soluble AChE activity was 825 
determined in conditioned media and expressed as percentage (%)with respect to control 826 
cells. (B) The accumulation of PRiMA was monitored with an anti-HA antibody. Data 827 
represent percentage of HA immunoreactivity relative to control cells. Data represent 828 
means ± SEM from at least 10 independent determinations from two independent 829 
experiments. *p < 0.05.   830 
831 
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 832 
Figure 5. Localization of PRiMA-HA immunoreactivity in the nucleus. (A) 833 
Confocal images of CHO cells stably overexpressing PS1 and co-transfected with 834 
PRiMA-HA. Cells were incubated for 24 hours with DMSO (control) or with 5 µM 835 
DAPT, fixed and immunodetection performed with an antibody against HA. Nuclei 836 
were stained with Hoechst 33258 dye. The insets show magnification of selected areas 837 
from the merged images, highlighting the low amount of PRiMA-HA in the nucleus 838 
after DAPT incubation. (B) Nuclear and cytoplasmic fractions from CHO-PS1/PRiMA 839 
cells were analyzed by Western blotting with an anti-HA antibody. A faint band of a C-840 
terminal PRiMA fragment (~14 kDa; arrow-head) was detected in the nuclear fraction 841 
while full length PRiMA was detected in the cytosolic fractions. Acetylated histone 842 
H2B (AcH2B) and tubulin were used as markers for nuclear and cytoplasmic fractions 843 
respectively. 844 
845 
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 846 
Figure 6. AChE co-localizes with PS1 within lipid rafts. a) H4 cell transiently 847 
expressing GFP-tagged PS1 (green), AChE (blue) and PRiMA. Lipid rafts are labelled 848 
in red. Binarised images of b) AChE, c) lipid raft and d) PS1 channels were generated to 849 
quantify co-localization with lipid rafts and PS1 using the Manders co-efficient (M; 850 
estimated in n= 7 cells). e) Pixels positive for both AChE and the lipid raft marker 851 
represent ~ 42± 3% of the total AChE-positive pixels. f) Pixels positive for both PS1 852 
and the lipid raft marker represent ~10± 1% of the total PS1-positive pixels. g) Pixels 853 
positive for AChE, PS1 and lipid raft marker constitute approximately ~23± 5% of 854 
AChE and ~26± 4% of PS1 that localize to the lipid rafts. 855 
856 
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 857 
Figure 7. G4 AChE is increased in membrane rafts isolated from the cortex of PS1 858 
cKO mice. Isolation of lipid rafts from cortices of 3-month old PS1 cKO mice (n= 6) 859 
and age-matched littermate controls (n= 6) was achieved by centrifugation in a 860 
discontinuous sucrose density gradient (fractions were collected from the top of the 861 
tubes).  (A) Raft-enriched fractions (fractions 2–6) and non-raft fractions (fractions 8–862 
12) were defined after determination of positive and negative lipid raft markers. Equal 863 
volumes from each fraction were analyzed by immunoblotting.  Flotilin 2 (Flt) and 864 
alkaline phosphatase enzymatic activity [ALP, expressed as arbitrary units (au)] were 865 
used as positive lipid raft markers, and Calnexin (Clnx) and β-cop, as non-lipid raft 866 
markers. (B) Raft localization of PS1 in control mice was verified by immunoblotting 867 
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with an anti–N-terminal PS1 antibody. Aliquots of all fractions were immunodetected 868 
with an anti–N-terminal antibody E19, which recognizes all the variant subunits of 869 
AChE.  AChE and PS1 were localized in lipid raft rich fractions as determined in (A). 870 
(C) Immunoblotting demonstrated increased AChE partitioning into lipid raft fractions 871 
in PS1 cKO versus control mice, as assessed by a ratio of the densitometric quantitation 872 
of the immunoreactivity of AChE bands identified in raft fractions 2–6 divided by the 873 
immunoreactivity of AChE bands identified in non-raft fractions 8–12. (D) 874 
Sedimentation analysis of raft-residing AChE (fractions 2-6) demonstrated a single 875 
molecular form corresponding to PRiMA-linked G4 AChE in both WT and PS1 cKO 876 
mice.877 
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878 
Additional Figure 1. Dose-dependent effect of the γ-secretase inhibitor DAPT on 879 
PRiMA processing. CHO cells stably transfected with the AChE-T variant and co-880 
transfected with the PRiMA subunit tagged to HA were treated with 0 (no treatment 881 
control), 0.1, 0.5, 1, 5 or 10 μM of DAPT. Cellular extracts immunoblotted with an anti-882 
HA antibody demonstrated increased PRiMA levels in treated cells. The results were 883 
confirmed in three independent experiments. 884 
885 
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 886 
Additional Figure 2. Unaltered levels of PRiMA in cells incubated with the AChE 887 
inhibitor fasciculin-2 and with the anti-AChE antibody HR2. CHO cells stably 888 
transfected with the AChE-T variant and co-transfected with PRiMA tagged to HA, 889 
were treated for 24 hours with fasciculin-2 (Fas2; 2 nM), or with the antibody HR2 890 
(dilution 1:1000). (A) The relative percentage of soluble AChE activity present in 891 
conditioned media after the addition of the specific reagent is shown. (B) 892 
Immunoreactivity of PRiMA-HA from treated cells. Each determination was made in 893 
duplicate. Data represent means ± SEM from at least 10 independent determinations 894 
from two independent experiments. *p < 0.05.   895 
896 
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 897 
Additional Figure 3. Levels of AChE remain unchanged in the PS1 cKO mouse 898 
brain. (A) Levels of AChE specific activity and (B) of PRiMA (assessed by a 899 
commercially available ELISA kit for mouse PRiMA) were measured in cortical 900 
extracts from 3-month old PS1 cKO mice (n= 6) and age-matched littermate controls 901 
(wild type: WT; n= 6). No difference in activity (AChE) or levels (PRiMA) was 902 
observed between WT and PS1 cKO mice. (C) Representative profiles and levels of 903 
molecular AChE forms in cortical extracts are also presented. The major AChE 904 
component corresponds to amphiphilic tetramers (G4), with minor amounts of 905 
monomeric forms (G1). No significant difference in levels was observed between WT 906 
and PS1 cKO mice. 907 
